LY294002 (PI 3 Kinase Inhibitor, 2-(4-Morpholinyl)-8-phenyl-4H-1-|benzopyran-4-one)
LY294002 is a potent and specific cell-permeable inhibitor of phosphatidylinositol 3-kinase (PI3-kinase). LY294002 at a concentration of 50uM completely abolishes the PI3-K activity of intact neutrophils stimulated with fMet-Leu-Phe, without apparent cell toxicity. While concentration of 50uM is observed to be efficacious for inhibiting PI3-K activity in stimulated neutrophils, this concentration produces no significant inhibition of other kinases including PKC, PKA, MAP kinase, S6 kinase, EGF receptor tyrosine kinase, Src, PI4-kinase, diacylglycerol kinase, or rabbit kidney ATPase. This compound is a useful tool for identifying cellular event that are regulated by the PI3-kinase/Akt axis, and is observed to induce apoptosis in many cell types by blocking the PI3-kinase/Akt anti-apoptotic pathway.
LY294002 (PI3 Kinase Inhibitor) was shown to act in vivo as a highly selective inhibitor of phosphatidylinositol 3 (PI3) kinase. When used at a concentration of 50uM, it specifically abolished PI3 kinase activity (IC50=0.43ug/ml; 1.40uM) but did not inhibit other lipid and protein kinases such as PI4 kinase, PKC, MAP kinase or c-Src. LY294002 has been shown to block PI3 kinase-dependent Akt phosphorylation and kinase activity.
Applications
Sutiable for use in vitro and in vivo.
Recommended Dilutions
Cultured cells: Recommend treating the cells with LY294002 for one hour prior to, and for the duration of, the stimulation. Optimal dilutions to be determined by researher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Light sensitive. Aliquots are stable for 3 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Form
Supplied as a liquid in DMSO.
Important Note
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
